Tolvaptan - Latest Advances

Discovery of Non-benzoazacyclic V2R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Journal: Journal of medicinal chemistry

Published: November 29, 2025

Real-world evidence for using urine osmolality as a practical tool in tolvaptan dose optimization in patients with ADPKD.

Journal: Clinical nephrology

Published: November 27, 2025

Hyponatraemia and cancer.

Journal: Best practice & research. Clinical endocrinology & metabolism

Published: November 13, 2025

Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis.

Journal: The Cochrane database of systematic reviews

Published: November 10, 2025

Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.

Journal: Renal failure

Published: November 10, 2025

Decoding Hyponatremia: A Systematic Review of Diagnostic Pathways and Therapeutic Approaches Applied When Correction Fails.

Journal: Cureus

Published: November 05, 2025

Assessing ciliary function in polycystic kidney disease: beyond the kidney.

Journal: Acta clinica Belgica

Published: October 29, 2025

Thirst in heart failure: a neglected symptom with profound implications for patient management and quality of life.

Journal: Expert review of cardiovascular therapy

Published: October 18, 2025

Refractory SIAD Triggered by Herpes Zoster Ophthalmicus: Impact of Postherpetic Neuralgia on Hyponatremia Duration and the Role of Tolvaptan-A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: October 01, 2025

Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment.

Journal: Cureus

Published: September 28, 2025

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study.

Journal: Frontiers in pharmacology

Published: September 26, 2025

Response to Letter to the Editor from Sumi and Tominaga: "Tolvaptan versus fluid restriction in moderate-profound hyponatremia: An open-label randomized clinical trial".

Journal: The Journal of clinical endocrinology and metabolism

Published: September 16, 2025

Filters

Discovery of Non-benzoazacyclic V2R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Discovery of Non-benzoazacyclic V2R Antagonists for the Treatment of Autosomal Dominant Polycystic Kidney Disease.

Real-world evidence for using urine osmolality as a practical tool in tolvaptan dose optimization in patients with ADPKD.

Real-world evidence for using urine osmolality as a practical tool in tolvaptan dose optimization in patients with ADPKD.

Hyponatraemia and cancer.

Hyponatraemia and cancer.

Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis.

Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis.

Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.

Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.

Decoding Hyponatremia: A Systematic Review of Diagnostic Pathways and Therapeutic Approaches Applied When Correction Fails.

Decoding Hyponatremia: A Systematic Review of Diagnostic Pathways and Therapeutic Approaches Applied When Correction Fails.

Assessing ciliary function in polycystic kidney disease: beyond the kidney.

Assessing ciliary function in polycystic kidney disease: beyond the kidney.

Thirst in heart failure: a neglected symptom with profound implications for patient management and quality of life.

Thirst in heart failure: a neglected symptom with profound implications for patient management and quality of life.

Refractory SIAD Triggered by Herpes Zoster Ophthalmicus: Impact of Postherpetic Neuralgia on Hyponatremia Duration and the Role of Tolvaptan-A Case Report.

Refractory SIAD Triggered by Herpes Zoster Ophthalmicus: Impact of Postherpetic Neuralgia on Hyponatremia Duration and the Role of Tolvaptan-A Case Report.

Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment.

Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment.

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study.

Clinical trial on the pharmacokinetics, pharmacodynamics and safety of tolvaptan in healthy Chinese males: an open-label, single and multiple dosage, parallel group study.

Response to Letter to the Editor from Sumi and Tominaga: "Tolvaptan versus fluid restriction in moderate-profound hyponatremia: An open-label randomized clinical trial".

Response to Letter to the Editor from Sumi and Tominaga: "Tolvaptan versus fluid restriction in moderate-profound hyponatremia: An open-label randomized clinical trial".